Ключевые слова: антикоагулянтная терапия, пожилой возраст, фибрилляция предсердий, хроническая болезнь почек. Annotation
жүктеу/скачать 42,58 Kb.
|
| Список литературы:
1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018;137:e67492. 2. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (Lond, Engl) 2017;390:121159. 3. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:11027 4. Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:17381. 5. Goldstein BA, Arce CM, Hlatky MA, et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126:2293301. 6. Turakhia MP, Blankestijn PJ, Carrero J-J, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018;39:231425. 7. Bansal N, Xie D, Tao K, et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016;11:118996. 8. Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:62936. 9. Hwang HS, Park MW, Yoon HE, et al. Clinical significance of chronic kidney disease and atrial fibrillation on morbidity and mortality in patients with acute myocardial infarction. Am J Nephrol 2014;40:34552. 10. Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 2014;3:e001303. 11. Thongprayoon C, Chokesuwattanaskul R, Bathini T, et al. Epidemiology and prognostic importance of atrial fibrillation in kidney transplant recipients: a meta-analysis. J Clin Med 2018;7. 12. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:294653. 13. Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol 2016;27:282532. 14. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311(9):919‐928. 10.1001/jama.2014.1334. 15. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:33‐37. 16. Jun M, James MT, Ma Z, et al.; Alberta Kidney Disease Network. Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2017;69(6):734‐743. 10.1053/j.ajkd.2016.10.018. 17. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta‐analysis of observational studies. Chest. 2016;149(4):951‐959. 10.1378/chest.15-1719. 18. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE‐LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139‐1151. 10.1056/NEJMoa0905561. 19. Awesat J, Sagy I, Haviv YS, et al. Dabigatran‐induced nephropathy and its successful treatment with idarucizumab—case report and literature review. Thromb Res. 2018;169:120‐122. 10.1016/j.thromres.2018.07.019. 20. Patel MR, Mahaffey KW, Garg J, et al.; the ROCKET AF Steering Committee. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883‐891. 10.1056/NEJMoa1009638. 21. Granger CB, Alexander JH, McMurray JJV, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981‐992. 10.1056/NEJMoa1107039. 22. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF‐TIMI 48 Investigators.Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093‐2104. 10.1056/NEJMoa1310907. 23. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. New Engl J Med 2012;367:62535. 24. Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:247182. 25. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014;311:91928. 26. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:9838. 27. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:268996. 28. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098106. 29. January CT, Wann LS, Alpert JS, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1‐e76. 10.1016/j.jacc.2014.03.022. 30. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84(2):527‐539. 31. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet. 1994;343(8899):687‐691. 32. Adjusted‐dose warfarin versus low‐intensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation: stroke prevention in atrial fibrillation iII randomised clinical trial. Lancet. 1996;348(9028):633‐638. 33. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta‐analysis. Ann Intern Med. 1999;131(7):492‐501. 34. Hart RG, Pearce LA, Aguilar MI. Meta‐analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857‐867. 10.7326/0003-4819-146-12-200706190-00007. 15. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599‐2604. 10.2215/CJN.02400311. 35. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:26628. [21]. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196203. 36. Jun M, James MT, Ma Z, et al. Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation. Am J Kidney Dis 2017;69:73443. 37. Keskar V, McArthur E, Wald R, et al. The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation. Kidney Int 2017;91:92836. 38. Tan J, Bae S, Segal JB, et al. Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation. Nephrology (Carlton, Vic) 2019;24:23444. [25]. Kumar S, de Lusignan S, McGovern A, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ (Clin Res Ed) 2018;360:k342. 39. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed) 2009;339:b2700. 40. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:6035 41. Zhu W, Wan R, Liu F, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. J Am Heart Assoc 2016;5:e4006. [29]. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071104. 42. Marinigh R, Lane DA, Lip GYH. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57(12):1339‐1348. 10.1016/j.jacc.2010.12.013. 43. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662‐2668. 10.2215/CJN.04550511. 44. Providência R, Marijon E, Boveda S, et al. Meta‐analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114(4):646‐653. 10.1016/j.amjcard.2014.05.048. 45. Bonde AN, Lip GYH, Kamper A‐L, et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study. Stroke. 2016;47(11):2707‐2713. 10.1161/STROKEAHA.116.014422. 46. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893962. 47. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:26372. 48. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093100. 49. Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? JAMA 2014;311:9135. 50. van Gorp RH, Schurgers LJ. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients 2015;7:953857. 51. Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009;54:46877. 52. Banerjee A, Fauchier L, Vourc’h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014;145:137082. 53. Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open 2017;7:e014294. 54. Ng KP, Edwards NC, Lip GY, et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 2013;62:61532. 55. Brancaccio D, Neri L, Bellocchio F, et al. Patients' characteristics affect the survival benefit of warfarin treatment for hemodialysis patients with atrial fibrillation. A historical cohort study. Am J Nephrol. 2016;44(4):258‐267. 10.1159/000448898. 56. Olesen JB, Lip GYH, Kamper A‐L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625‐635. 10.1056/NEJMoa1105594. 57. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129(11):1196‐1203. 10.1161/CIRCULATIONAHA.113.004777. 58. Shen JI, Montez‐Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66(4):677‐688. 10.1053/j.ajkd.2015.05.019. 59. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223‐2233. 10.1681/ASN.2009030319. ] 60. Tan J, Liu S, Segal JB, Alexander GC, McAdams‐DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta‐analysis. BMC Nephrol. 2016;17(1):157 10.1186/s12882-016-0368-6. 61. Lee M, Saver JL, Hong K‐S, et al. Warfarin use and risk of stroke in patients with atrial fibrillation undergoing hemodialysis: a meta‐analysis. Medicine. 2016;95(6):e2741 10.1097/MD.0000000000002741. жүктеу/скачать 42,58 Kb. Достарыңызбен бөлісу:
|